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Table (according to actual treatment 
received)
IND (N= 41) CON (N= 29) p
Median RDI docetaxel (%) 99 93 NS
Median RDI cisplatin (%) 99 96 NS
Median RDI radiotherapy (%) 100 100 NS
Overall treatment time (days) 87 72 NS
Grade 3/4 neutropenia / 
febrile neutropenia (%) 22/5 41/17 0.08/0.09
Gr 3/4 esophagitis/pneumonitis (%) 34/10 28/10 0.56/0.96
Gr 3/4 nausea/vomiting (%) 5 14 0.18
Deaths during and within 30 d of treatment 0 2 0.09
Best response at end of treatment (%) 68 83 0.17
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Purpose: NQO1 is an enzyme that catalyzes the two-electron reduction 
of the more toxic quinone to less toxic hydroquinone. It is known that 
NQO1 may decrease the risk of cancer development in normal human 
tissue, and NQO1 polymorphism affect on the treatment outcome after 
chemotherapy in lung cancer. We investigated the effect of NQO1 
polymorphism on radiation therapy through the difference of survival 
outcome by NQO1 different genotypes in non-small cell lung cancer 
(NSCLC) patients treated with surgery followed by postoperative radia-
tion therapy.
Methods: One hundred and ﬁfty-two patients (Male: 116, Female: 
36) who were histologically proven NSCLC and treated with surgery 
and postoperative radiation therapy from Jan 2000 to Aug 2005 were 
analyzed. We determined NQO1 genotypes from peripheral blood of 
patients. NQO1 genotypes were classiﬁed as three groups, and each 
genotype had different enzymatic activities; C/C is the wild type with 
normal activity, C/T is the heterozygous type with decreased activity, 
and T/T is the homozygous mutation with no enzymatic activity. There-
after, we analyzed the correlation between NQO1 genotypes and the 
survival outcome after surgery and postoperative radiation therapy. For 
the authenticity of genotype from peripheral blood, genotypic analysis 
directly from tumor tissue was performed.
Results: Numbers of patients in each NQO1 genotype were 41 patients 
for C/C, 83 patients for C/T, and 28 patients for T/T. Patients character-
istics with sex, age, clinical stage, pathology, and combined chemo-
therapy were not different between genotypic groups. Median fol-
low-up period was 19.7 months. NQO1 genotype had an effect on the 
actuarial loco-regional control and survival. Patients expressing C/C 
and C/T genotype with NQO1 enzymatic activity had a signiﬁcantly 
longer loco-regional progression free survival (89.2% vs. 68.3% at 2yr) 
and overall survival (90.2% vs. 70.6% at 2yr) than patients expressing 
T/T genotype (p=0.034). Genotypic analysis from tumor tissue was 
performed in only eighteen patients. There was accordance in sixteen 
patients between the genotype from peripheral blood and that directly 
from tumor tissue, and the other two patients with C/C genotype in 
blood expressed C/T in tumor tissue.
Conclusions: NQO1 polymorphisms affected on treatment results 
in NSCLC patients treated with surgery and postoperative radiation 
therapy. NQO1 could be a useful prognostic factor for NSCCL after 
radiation therapy, although the further study with more patients and 
long-term follow-up should be promised.
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Introduction: Lung cancer is an increasing problem in developing 
countries, where access to medical resources may be limited. It is 
crucial that care in these settings makes most effective and cost effec-
tive use of those resources, based on good evidence. Clinical guideline 
recommendations from developed countries are not likely to be always 
(or ever) appropriate and so a different approach is needed.
Methods: An international panel, with a special interest in lung cancer, 
was invited to a meeting organised by the IAEA in March 2006, at 
which the main approaches were drafted. Reference was made to recent 
English language evidence-based clinical guidelines and to other recent 
systematic reviews, meta-analyses and research. Drafts were then circu-
lated sequentially around the group members, a telephone conference 
held and a ﬁnal version approved. We assumed that baseline resources 
for diagnosis (including CT scanning), radical surgery, radiotherapy 
(RT) with at least 60Co and 2D planning and IV cisplatin-based combi-
nation chemotherapy (CT) would be available. Tables were constructed 
that showed a baseline standard treatment for different patient groups 
and the additional beneﬁts, risks and resource use from additional 
treatment options. Accompanying text summarised the evidence and 
justiﬁcation for these options.
Results: Six tables were devised entitled:
1. Options for patients with limited disease SCLC and good prognosis
2. Options for patients with operable NSCLC
3. RT options for patients with medically inoperable NSCLC (Stage I 
and II)
4. Options for patients with inoperable ‘small’ volume NSCLC (‘Fa-
vourable’ Stage III)
5. Options for palliative thoracic RT
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6. Options for patients with ‘unfavourable’ Stage III and Stage IV 
disease and WHO PS 0 or 1.
A comprehensive list of 65 relevant references to current clinical guide-
lines, systematic reviews and primary research was included.
Discussion: We believe that this is an innovative approach to guideline 
development because it not only summarises the research evidence but 
makes clear the additional resource use and risks as well as beneﬁts of 
treatment options. This would enable people to make local decisions 
about best use of their resources or to develop more sophisticated cost 
effectiveness models for their local health services. It will also allow 
those without even the baseline resources to lobby for their provision.
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Background: Lung cancer is the leading cause of cancer mortality in 
Australia. However little is known about patient management of this 
disease in Australia. Previous patterns of care studies showed variabil-
ity in patient management and a signiﬁcant proportion of patients not 
receiving anti-cancer treatment. 
Methods: Lung cancer patients were prospectively identiﬁed from the 
NSW Central Cancer Registry (CCR) from 1 November 2001 to 31 
December 2002. After obtaining patient and/or doctor consent, four 
separate questionnaires were used to collect information on diagnosis, 
staging, referrals and treatment. Factors related to patients not receiving 
treatment were examined using cross-tabulations and logistic regression. 
Results: There were 2931 potentially eligible patients registered by the 
CCR of whom 2126 (76%) consented to participate. The study sample 
comprised 1812 patients (62%) with completed questionnaires. The me-
dian age was 71 years with 66% being male. ECOG performance status 
was rated as good (ECOG 0-2) in 74% of patients. The pathology was 
non-small cell in 71%, small cell in 16% and not conﬁrmed in 13%. 
Eleven percent of patients did not see a lung cancer specialist and 33% 
received no treatment at initial diagnosis. Treatment utilisation rates 
were 17% for surgery, 39% for radiotherapy and 30% for chemothera-
py. Of the patients who did not receive initial treatment, 6% of patients 
refused treatment, 28% were deemed unﬁt for treatment by a surgeon or 
oncologist and 57% were deemed unsuitable for treatment by another 
doctor. Female gender, older age, weight loss and poorer performance 
status were patient factors signiﬁcantly associated with no treatment. 
Patients who did not see a cardiothoracic surgeon or radiation oncolo-
gist and those seeing a clinician who saw <10 lung cancer patients 
during the study period were less likely to have treatment. The median 
survival was 172 days and 2 year crude overall survival was 17%.
Conclusions: A signiﬁcant proportion of patients did not receive treat-
ment for their lung cancer. In most cases this decision was made by a 
doctor not involved in lung cancer treatment and who was not the best 
qualiﬁed to outline the risks and beneﬁts associated with treatment. 
Modifying health care provider behaviour is necessary as a major step 
in improving lung cancer care in NSW.
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Background: In selected cases of bronchogenic carcinoma, sleeve 
lobectomy is a valid alternative to pneumonectomy with the advantage 
of preserving functional lung parenchyma as the reimplanted lobes 
contribute to postoperative lung function. The objective of the present 
study is to evaluate quality of life evolution after sleeve lobectomy and 
pneumonectomy for lung cancer, which has not been studied prospec-
tively until now. 
Methods: A prospective quality of life registration started in 2003 for 
all patients undergoing major pulmonary surgery for malignant lung dis-
ease. The European Organisation for Research and Treatment of Cancer 
(EORTC) Quality of Life Questionnaire-C30 and the lung cancer speciﬁc 
module LC13 were used. Between January 2003 and December 2005, 
10 sleeve lobectomies and 20 pneumonectomies were included. Both 
resections were comparable in population characteristics, surgical access, 
adjuvant treatment and histological diagnosis. Both resections were 
comparable in pTNM classiﬁcation with exception of a signiﬁcant higher 
number of T3N1M0 tumours in the pneumonectomy group (p=0.046). 
Quality of life questionnaires were administered preoperatively and 1, 
3, 6 and 12 months postoperatively (MPO) with response rates of 100%, 
90.0%, 76.7%, 80.0% and 73.3%, respectively. 
Results: Both surgical resections were comparable in pre-operative base-
line quality of life subscale scores. Sleeve lobectomy was characterized 
by a one month temporary decrease in physical and social functioning 
scores after surgery (1MPO p=0.026 and p=0.048, respectively). After 
sleeve lobectomy, quality of life, symptom and pain scores approximated 
baseline pre-operative values one month after surgery. 
Pneumonectomy had a signiﬁcant impact on physical and role function-
ing. In the twelve months follow-up period, there was no return to 
baseline in physical and role functioning (1MPO p=0.001 and p=0.001, 
3MPO p=0.002 and p=0.006, 6MPO p=0.001 and 0.002, 12MPO 
p=0.001 and p=0.011, respectively). Pneumonectomy patients reported 
a signiﬁcant increase in postoperative dyspnea (1MPO p=0.027, 
6MPO p=0.025, 12MPO 0.021), general pain (1MPO p=0.006, 3MPO 
p=0.008, 6MPO p=0.005, 12MPO p=0.036), thoracic pain (6MPO 
p=0.019) and shoulder dysfunction ( 6MPO p=0.04, 12MPO p=0.026), 
not reported after sleeve lobectomy. 
Comparing sleeve lobectomy to pneumonectomy, signiﬁcant differ-
ences in evolution of physical functioning (1MPO p=0.014, 3MPO 
p=0.008, 6MPO p=0.004), role functioning (1MPO p=0.041), cognitive 
functioning (6MPO p=0.005, 12MPO p=0.013) and shoulder dysfunc-
tion (12MPO p=0.049) were reported in favor of sleeve lobectomy. 
Conclusions: The present study prospectively documents quality of 
life evolution proﬁles comparing preoperative status with deﬁcits and 
changes at 1, 3, 6 and 12 months after sleeve lobectomy and pneumo-
nectomy. With exception of a one month temporary decrease in physi-
cal and social functioning, sleeve lobectomy patients return to their 
baseline quality of life in less than one month after surgery. In contrast, 
pneumonectomy patients report a sustained decrease of physical and 
role functioning in the twelve month follow-up period. The high burden 
of dyspnea, general pain, thoracic pain and shoulder dysfunction 
reported after pneumonectomy, is not seen after sleeve lobectomy. In 
patients with anatomically appropriate early-stage lung cancer, sleeve 
lobectomy offers better quality of life than does pneumonectomy.
